Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Employees

277

Sector

Biotechnology & Medical Research

More about the company

21/24/21	AbbVie CEO to Retire; COO Robert Michael Named Successor	MT
13/24/13	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	AN
13/24/13	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	MT
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	CI
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	CI
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	CI
12/24/12	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	MT
12/24/12	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	MT
12/24/12	AbbVie: acquisition of ImmunoGen finalized
12/24/12	AbbVie Acquires ImmunoGen for $31.26 per Share	MT
12/24/12	Immunogen, Inc. Announces Board Changes	CI
12/24/12	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	CI
12/24/12	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	CI

04/23/04	Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	MT
01/23/01	Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	MT
01/23/01	Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	MT
01/23/01	BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	MT
01/23/01	Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	MT

12/24/12	AbbVie Completes Acquisition of ImmunoGen	PR
02/24/02	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/24/04	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
04/24/04	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/23/10	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU

12/24/12	Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street
12/24/12	Abbvie : abaisse ses perspectives après le rachat d'Immunogen
12/24/12	AbbVie : acquisition d'ImmunoGen finalisée
02/24/02	Omzetdaling Abbvie valt mee
22/24/22	HBM bleibt nach neun Monaten in den roten Zahlen

Manager	Title	Age	Since
Stacy Coen PRN	Corporate Officer/Principal	55	03/06/2020
Theresa Wingrove CTO	Chief Tech/Sci/R&D Officer	68	24/01/2011

ImmunoGen, Inc. Share Price

Stocks

IMGN

US45253H1014

Biotechnology & Medical Research

Latest news: ImmunoGen, Inc.

Analysts' recommendations: ImmunoGen, Inc.

Press Releases: ImmunoGen, Inc.

News in other languages: ImmunoGen, Inc.

Managers and Directors: ImmunoGen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/24	Isabel Kalofonos	Issuer sale	Executive/Senior Manager	3,51,083	0.1257%
12/02/24	Tracey McCain	Issuer sale	Director	1,52,546	0.0546%
12/02/24	Renee Lentini	Issuer sale	VP & PRIN ACCTG OFFICER	2,21,353	0.0792%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOGEN, INC.	-.--%	+6.73%	-	-	835.91Cr
WUXI APPTEC CO., LTD.	+0.34%	+1.12%	+34.75%	+61.06%	6.44TCr
ARGENX SE	+0.98%	+2.68%	+12.25%	+82.98%	5.62TCr
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+103.69%	5.42TCr
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+52.86%	4.53TCr
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+117.99%	4.22TCr
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+922.41%	4.08TCr
GENMAB A/S	-2.07%	+42.73%	+103.77%	+88.74%	3.38TCr
CELLTRION, INC.	-0.26%	-2.57%	+12.55%	+45.18%	3.22TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.73%	-3.19%	+21.21%	-12.20%	2.36TCr
Average	-0.19%	+4.50%	+52.23%	+162.52%	4.36TCr
Weighted average by Cap.	+0.01%	+3.60%	+49.16%	+161.39%